RÉSUMÉ
BACKGROUND: Non-pharmaceutical measures and travel restrictions have halted the spread of coronavirus disease 2019 (COVID-19) and influenza. Nonetheless, with COVID-19 restrictions lifted, an unanticipated outbreak of the influenza B/Victoria virus in late 2021 and another influenza H3N2 outbreak in mid-2022 occurred in Guangdong, southern China. The mechanism underlying this phenomenon remains unknown. To better prepare for potential influenza outbreaks during COVID-19 pandemic, we studied the molecular epidemiology and phylogenetics of influenza A(H3N2) and B/Victoria that circulated during the COVID-19 pandemic in this region. METHODS: From January 1, 2018 to December 31, 2022, we collected throat swabs from 173,401 patients in Guangdong who had acute respiratory tract infections. Influenza viruses in the samples were tested using reverse transcription-polymerase chain reaction, followed by subtype identification and sequencing of hemagglutinin (HA) and neuraminidase (NA) genes. Phylogenetic and genetic diversity analyses were performed on both genes from 403 samples. A rigorous molecular clock was aligned with the phylogenetic tree to measure the rate of viral evolution and the root-to-tip distance within strains in different years was assessed using regression curve models to determine the correlation. RESULTS: During the early period of COVID-19 control, various influenza viruses were nearly undetectable in respiratory specimens. When control measures were relaxed in January 2020, the influenza infection rate peaked at 4.94% (39/789) in December 2021, with the influenza B/Victoria accounting for 87.18% (34/39) of the total influenza cases. Six months later, the influenza infection rate again increased and peaked at 11.34% (255/2248) in June 2022; influenza A/H3N2 accounted for 94.51% (241/255) of the total influenza cases in autumn 2022. The diverse geographic distribution of HA genes of B/Victoria and A/H3N2 had drastically reduced, and most strains originated from China. The rate of B/Victoria HA evolution (3.11 × 10-3, P < 0.05) was 1.7 times faster than before the COVID-19 outbreak (1.80 × 10-3, P < 0.05). Likewise, the H3N2 HA gene's evolution rate was 7.96 × 10-3 (P < 0.05), which is 2.1 times faster than the strains' pre-COVID-19 evolution rate (3.81 × 10-3, P < 0.05). CONCLUSIONS: Despite the extraordinarily low detection rate of influenza infection, concealed influenza transmission may occur between individuals during strict COVID-19 control. This ultimately leads to the accumulation of viral mutations and accelerated evolution of H3N2 and B/Victoria viruses. Monitoring the evolution of influenza may provide insights and alerts regarding potential epidemics in the future.
Sujet(s)
COVID-19 , Sous-type H3N2 du virus de la grippe A , Virus influenza B , Grippe humaine , Épidémiologie moléculaire , Phylogenèse , SARS-CoV-2 , Humains , COVID-19/épidémiologie , COVID-19/virologie , COVID-19/transmission , Sous-type H3N2 du virus de la grippe A/génétique , Sous-type H3N2 du virus de la grippe A/isolement et purification , Chine/épidémiologie , Grippe humaine/épidémiologie , Grippe humaine/virologie , Virus influenza B/génétique , Virus influenza B/isolement et purification , Virus influenza B/classification , SARS-CoV-2/génétique , Adulte , Adulte d'âge moyen , Mâle , Femelle , Pandémies , Jeune adulte , Sujet âgé , Glycoprotéine hémagglutinine du virus influenza/génétique , Adolescent , Sialidase/génétique , Enfant , Enfant d'âge préscolaireRÉSUMÉ
Introduction: Seasonal influenza generally represents an underestimated public health problem with significant socioeconomic implications. Monitoring and detecting influenza epidemics are important tasks that require integrated strategies. Wastewater-based epidemiology (WBE) is an emerging field that uses wastewater data to monitor the spread of disease and assess the health of a community. It can represent an integrative surveillance tool for better understanding the epidemiology of influenza and prevention strategies in public health. Methods: We conducted a study that detected the presence of Influenza virus RNA using a wastewater-based approach. Samples were collected from five wastewater treatment plants in five different municipalities, serving a cumulative population of 555,673 Sicilian inhabitants in Italy. We used the RT-qPCR test to compare the combined weekly average of Influenza A and B viral RNA in wastewater samples with the average weekly incidence of Influenza-like illness (ILI) obtained from the Italian national Influenza surveillance system. We also compared the number of positive Influenza swabs with the viral RNA loads detected from wastewater. Our study investigated 189 wastewater samples. Results: Cumulative ILI cases substantially overlapped with the Influenza RNA load from wastewater samples. Influenza viral RNA trends in wastewater samples were similar to the rise of ILI cases in the population. Therefore, wastewater surveillance confirmed the co-circulation of Influenza A and B viruses during the season 2022/2023, with a similar trend to that reported for the weekly clinically confirmed cases. Conclusion: Wastewater-based epidemiology does not replace traditional epidemiological surveillance methods, such as laboratory testing of samples from infected individuals. However, it can be a valuable complement to obtaining additional information on the incidence of influenza in the population and preventing its spread.
Sujet(s)
Virus de la grippe A , Grippe humaine , Eaux usées , Sicile/épidémiologie , Humains , Grippe humaine/épidémiologie , Grippe humaine/virologie , Eaux usées/virologie , Virus de la grippe A/isolement et purification , Virus de la grippe A/génétique , Saisons , Virus influenza B/isolement et purification , Virus influenza B/génétique , ARN viral/analyse , Villes/épidémiologieRÉSUMÉ
BACKGROUND: Influenza viruses pose a persistent threat to global public health, necessitating the development of innovative and broadly effective vaccines. METHODS: This study focuses on a multiepitope vaccine (MEV) designed to provide broad-spectrum protection against different influenza viruses. The MEV, containing 19 B-cell linear epitopes, 7 CD4+ T cells, and 11 CD8+ T cells epitopes identified through enzyme-linked immunospot assay (ELISPOT) in influenza viruses infected mice, was administered through a regimen of two doses of DNA vaccine followed by one dose of a protein vaccine in C57BL/6 female mice. FINDINGS: Upon lethal challenge with both seasonal circulating strains (H1N1, H3N2, BV, and BY) and historical strains (H1N1-PR8 and H3N2-X31), MEV demonstrated substantial protection against different influenza seasonal strains, with partial efficacy against historical strains. Notably, the increased germinal centre B cells and antibody-secreting cells, along with robust T cell immune responses, highlighted the comprehensive immune defence elicited by MEV. Elevated hemagglutinin inhibition antibody was also observed against seasonal circulating and historical strains. Additionally, mice vaccinated with MEV exhibited significantly lower counts of inflammatory cells in the lungs compared to negative control groups. INTERPRETATION: Our results demonstrated the efficacy of a broad-spectrum MEV against influenza viruses in mice. Conducting long-term studies to evaluate the durability of MEV-induced immune responses and explore its potential application in diverse populations will offer valuable insights for the continued advancement of this promising vaccine. FUNDING: Funding bodies are described in the Acknowledgments section.
Sujet(s)
Déterminants antigéniques des lymphocytes B , Virus influenza B , Vaccins antigrippaux , Infections à Orthomyxoviridae , Animaux , Vaccins antigrippaux/immunologie , Vaccins antigrippaux/administration et posologie , Souris , Virus influenza B/immunologie , Infections à Orthomyxoviridae/prévention et contrôle , Infections à Orthomyxoviridae/immunologie , Femelle , Déterminants antigéniques des lymphocytes B/immunologie , Virus de la grippe A/immunologie , Anticorps antiviraux/immunologie , Déterminants antigéniques des lymphocytes T/immunologie , Modèles animaux de maladie humaine , Souris de lignée C57BL , Vaccins à ADN/immunologie , Vaccins à ADN/administration et posologie , Saisons , Sous-type H3N2 du virus de la grippe A/immunologie , HumainsRÉSUMÉ
Matrix protein 2 (M2) and matrix protein 1 (M1) of the influenza B virus are two important proteins, and the interactions between BM2 and BM1 play an important role in the process of virus assembly and replication. However, the interaction details between BM2 and BM1 are still unclear at the atomic level. Here, we constructed the BM2-BM1 complex system using homology modelling and molecular docking methods. Molecular dynamics (MD) simulations were used to illustrate the binding mechanism between BM2 and BM1. The results identify that the eight polar residues (E88B, E89B, H119BM1, E94B, R101BM1, K102BM1, R105BM1, and E104B) play an important role in stabilizing the binding through the formation of hydrogen bond networks and salt-bridge interactions at the binding interface. Furthermore, based on the simulation results and the experimental facts, the mutation experiments were designed to verify the influence of the mutation of residues both within and outside the effector domain. The mutations directly or indirectly disrupt interactions between polar residues, thus affecting viral assembly and replication. The results could help us understand the details of the interactions between BM2 and BM1 and provide useful information for the anti-influenza drug design.
Sujet(s)
Simulation de dynamique moléculaire , Liaison aux protéines , Électricité statique , Protéines de la matrice virale , Protéines de la matrice virale/composition chimique , Protéines de la matrice virale/métabolisme , Virus influenza B/composition chimique , Virus influenza B/métabolisme , Liaison hydrogène , Simulation de docking moléculaire , Mutation , Sites de fixation , Protéines viralesRÉSUMÉ
Influenza is a highly contagious acute viral illness that affects the respiratory system, posing a significant global public health concern. Influenza B virus (IBV) causes annual seasonal epidemics. The exploration of molecular biology and reverse genetics of IBV is pivotal for understanding its replication, pathogenesis, and evolution. Reverse genetics empowers us to purposefully alter the viral genome, engineer precise genetic modifications, and unveil the secrets of virulence and resistance mechanisms. It helps us in quickly analyzing new virus strains by viral genome manipulation and the development of innovative influenza vaccines. Reverse genetics has been employed to create mutant or reassortant influenza viruses for evaluating their virulence, pathogenicity, host range, and transmissibility. Without this technique, these tasks would be difficult or impossible, making it crucial for preparing for epidemics and protecting public health. Here, we bring together the latest information on how we can manipulate the genes of the influenza B virus using reverse genetics methods, most importantly helper virus-independent techniques.
Sujet(s)
Virus influenza B , Vaccins antigrippaux , Grippe humaine , Génétique inverse , Virus influenza B/génétique , Virus influenza B/immunologie , Génétique inverse/méthodes , Humains , Grippe humaine/prévention et contrôle , Grippe humaine/épidémiologie , Grippe humaine/virologie , Vaccins antigrippaux/génétique , Vaccins antigrippaux/immunologie , Génome viral , Animaux , Développement de vaccin , Biologie moléculaire/méthodes , Virulence/génétique , Épidémies/prévention et contrôleRÉSUMÉ
BACKGROUND: Influenza represents a significant global health burden for individuals and society. This study assessed the burden of medically attended influenza at a tertiary medical center in Lebanon to describe the demographics, risk factors, and outcomes prior to the COVID-19 pandemic. METHODS: This was a retrospective review of patients who tested positive for the influenza virus during three seasons between July 1, 2016 to June 30, 2019, at the American University of Beirut Medical Center. RESULTS: A total of 2049 patients who tested positive for influenza were analyzed. Influenza A accounted for 79.6 % of cases, and influenza B for 19.7 %, with influenza activity starting in October/November and peaking in December/January. Older age above 65 years (AOR=3.584), obesity (AOR=2.183), and chronic conditions such as chronic lung diseases (AOR=1.832), and bacterial co-infection (AOR= 2.834) were found to be independent risk factors for developing complications. Viral co-infection increased the likelihood of death tenfold. Vaccinated patients had a shorter mean hospital stay duration and a lower intensive care unit admission rate. CONCLUSION: The burden of medically attended influenza at our tertiary medical center in Lebanon prior to the COVID-19 pandemic was high. Vaccination decreased the likelihood of complications leading to intensive care unit admission in patients at risk.
Sujet(s)
COVID-19 , Grippe humaine , Humains , Liban/épidémiologie , Grippe humaine/épidémiologie , Mâle , Femelle , Études rétrospectives , Sujet âgé , Adulte d'âge moyen , Adulte , COVID-19/épidémiologie , Facteurs de risque , Jeune adulte , Adolescent , Centres de soins tertiaires/statistiques et données numériques , Enfant , Sujet âgé de 80 ans ou plus , Facteurs âges , Hospitalisation/statistiques et données numériques , Enfant d'âge préscolaire , Co-infection/épidémiologie , Nourrisson , Virus influenza B , SARS-CoV-2 , Virus de la grippe ARÉSUMÉ
The multiplex molecular diagnostic assays described for severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), influenza A (IAV) and B (IBV) viruses have been mainly based on real-time reaction, which limits their access to many laboratories or diagnostic institutions. To contribute to available strategies and expand access to differential diagnosis, we describe an end-point multiplex RT-PCR targeting SARS-CoV-2, IAV and IBV with simultaneous endogenous control amplification. Initially, we looked for well-established primers sets for SARS-CoV-2, IAV, IBV and RNAse P whose amplicons could be distinguished on agarose gel. The multiplex assay was then standardized by optimizing the reaction mix and cycle conditions. The limit of detection (LoD) was determined using titrated viruses (for SARS-CoV-2 and IAV) and by dilution from a pool of IBV-positive samples. The diagnostic performance of the multiplex was evaluated by testing samples with different RNAse P and viral loads, previously identified as positive or negative for the target viruses. The amplicons of IAV (146 bp), SARS-CoV-2 (113 bp), IBV (103 bp) and RNAse P (65 bp) were adequately distinguished in our multiplex. The LoD for SARS-CoV-2, IAV and IBV was 0.02 TCID50/ml, 0.07 TCID50/ml and 10-3 from a pool of positive samples, respectively. All samples positive for SARS-CoV-2 (n=70, Ct 17.2-36.9), IAV (n=53, Ct 14-34.9) and IBV (n=12, Ct 23.9-31.9) remained positive in our multiplex assay. RNAse P from negative samples (n=40, Ct 25.2-30.2) was also amplified in the multiplex. Overall, our assay is a timely and alternative tool for detecting SARS-CoV-2 and influenza viruses in laboratories with limited access to supplies/equipment.
Sujet(s)
COVID-19 , Virus de la grippe A , Virus influenza B , Réaction de polymérisation en chaine multiplex , Ribonuclease P , SARS-CoV-2 , Humains , Ribonuclease P/génétique , SARS-CoV-2/génétique , SARS-CoV-2/isolement et purification , Virus de la grippe A/isolement et purification , Virus de la grippe A/génétique , Virus influenza B/isolement et purification , Virus influenza B/génétique , COVID-19/diagnostic , COVID-19/virologie , Réaction de polymérisation en chaine multiplex/méthodes , Diagnostic différentiel , Grippe humaine/diagnostic , Grippe humaine/virologie , Sensibilité et spécificité , RT-PCR/méthodes , Limite de détection , ARN viral/génétique , ARN viral/analyseRÉSUMÉ
Influenza virus is a well-known pathogen that can cause epidemics and pandemics. Several surveillance methods are being followed to monitor the transmission patterns and spread of influenza in the community. Wastewater-based Epidemiology (WBE) can serve as an additional tool to detect the presence of influenza viruses. The current study primarily focuses on surveillance of Influenza A and Influenza B in wastewater treatment plant (WWTP) samples. A total of 100 wastewater samples were collected in July (n = 50) and August (n = 50) 2023 from four different WWTPs in Manipal and Udupi, district of Karnataka, India. The WWTP samples were processed and tested by Real-Time reverse transcriptase PCR (RT-PCR). The data generated was analysed in comparison with the clinical Influenza cases. Of the 100 samples, 18 (18%) tested positive for Influenza A virus and 2 (2%) tested positive for Influenza B virus, with a viral load ranging 1.4 x 102-2.2 x 103 gc/L for influenza A virus and 5.2 x 103-7.7 x 103gc/L for influenza B virus. On correlating the WWTP positivity with clinical case, it was found that influenza clinical cases and virus positivity in wastewater increased simultaneously, emphasizing WBE as a concurrent method for monitoring influenza virus activity.
Sujet(s)
Hôpitaux , Virus de la grippe A , Virus influenza B , Grippe humaine , Eaux usées , Eaux usées/virologie , Virus influenza B/isolement et purification , Virus influenza B/génétique , Virus de la grippe A/génétique , Virus de la grippe A/isolement et purification , Humains , Inde/épidémiologie , Grippe humaine/virologie , Grippe humaine/épidémiologie , Purification de l'eau , Charge virale , Réaction de polymérisation en chaine en temps réelRÉSUMÉ
Influenza virus infection poses a continual menace to public health. Here, we developed soluble trimeric HA ectodomain vaccines by establishing interprotomer disulfide bonds in the stem region, which effectively preserve the native antigenicity of stem epitopes. The stable trimeric H1 ectodomain proteins exhibited higher thermal stabilities in comparison with unmodified HAs and showed strong binding activities towards a panel of anti-stem cross-reactive antibodies that recognize either interprotomer or intraprotomer epitopes. Negative stain transmission electron microscopy (TEM) analysis revealed the stable trimer architecture of the interprotomer disulfide-stapled WA11#5, NC99#2, and FLD#1 proteins as well as the irregular aggregation of unmodified HA molecules. Immunizations of mice with those trimeric HA ectodomain vaccines formulated with incomplete Freund's adjuvant elicited significantly more potent cross-neutralizing antibody responses and offered broader immuno-protection against lethal infections with heterologous influenza strains compared to unmodified HA proteins. Additionally, the findings of our study indicate that elevated levels of HA stem-specific antibody responses correlate with strengthened cross-protections. Our design strategy has proven effective in trimerizing HA ectodomains derived from both influenza A and B viruses, thereby providing a valuable reference for designing future influenza HA immunogens.
Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , Disulfures , Glycoprotéine hémagglutinine du virus influenza , Vaccins antigrippaux , Souris de lignée BALB C , Infections à Orthomyxoviridae , Animaux , Vaccins antigrippaux/immunologie , Vaccins antigrippaux/génétique , Glycoprotéine hémagglutinine du virus influenza/immunologie , Glycoprotéine hémagglutinine du virus influenza/génétique , Glycoprotéine hémagglutinine du virus influenza/composition chimique , Anticorps antiviraux/immunologie , Souris , Disulfures/composition chimique , Infections à Orthomyxoviridae/prévention et contrôle , Infections à Orthomyxoviridae/immunologie , Infections à Orthomyxoviridae/virologie , Anticorps neutralisants/immunologie , Femelle , Protection croisée/immunologie , Réactions croisées , Humains , Grippe humaine/prévention et contrôle , Grippe humaine/immunologie , Grippe humaine/virologie , Épitopes/immunologie , Épitopes/génétique , Épitopes/composition chimique , Multimérisation de protéines , Virus influenza B/immunologie , Virus influenza B/génétique , Virus influenza B/composition chimiqueRÉSUMÉ
The COVID-19 pandemic, in addition to the co-occurrence of influenza virus and respiratory syncytial virus (RSV), has emphasized the requirement for efficient and reliable multiplex diagnostic methods for respiratory infections. While existing multiplex detection techniques are based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) and extraction and purification kits, the need for complex instrumentation and elevated cost limit their scalability and availability. In this study, we have developed a point-of-care (POC) device based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) that can simultaneously detect four respiratory viruses (SARS-CoV-2, Influenza A, Influenza B, and RSV) and perform two controls in less than 30 min, while avoiding the use of the RNA extraction kit. The system includes a disposable microfluidic cartridge with mechanical components that automate sample processing, with a low-cost and portable optical reader and a smartphone app to record and analyze fluorescent images. The application as a real point-of-care platform was validated using swabs spiked with virus particles in nasal fluid. Our portable diagnostic system accurately detects viral RNA specific to respiratory pathogens, enabling deconvolution of coinfection information. The detection limits for each virus were determined using virus particles spiked in chemical lysis buffer. Our POC device has the potential to be adapted for the detection of new pathogens and a wide range of viruses by modifying the primer sequences. This work highlights an alternative approach for multiple respiratory virus diagnostics that is well-suited for healthcare systems in resource-limited settings or at home.
Sujet(s)
Techniques d'amplification d'acides nucléiques , Systèmes automatisés lit malade , SARS-CoV-2 , Humains , SARS-CoV-2/isolement et purification , SARS-CoV-2/génétique , Techniques d'amplification d'acides nucléiques/méthodes , Virus de la grippe A/isolement et purification , Virus de la grippe A/génétique , COVID-19/diagnostic , COVID-19/virologie , Virus influenza B/isolement et purification , Virus influenza B/génétique , ARN viral/analyse , ARN viral/isolement et purification , ARN viral/génétique , Techniques de diagnostic moléculaire/méthodes , Infections de l'appareil respiratoire/diagnostic , Infections de l'appareil respiratoire/virologie , Virus respiratoires syncytiaux/isolement et purification , Virus respiratoires syncytiaux/génétiqueRÉSUMÉ
BACKGROUND: Influenza B virus induced myocarditis is a rare complication with potentially wide variations in severity and clinical presentation, and the pathogenesis is unclear. CASE PRESENTATION: We describe a rare case of a 7-year-old boy who developed fulminant myocarditis (FM) due to influenza B virus infection. Treatment measures included mechanical ventilation, vasoactive agents, Extracorporeal membrane oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), anti-inflammatory, antiviral, anti-infection, and enteral nutrition support. After 10 days of treatment, the patient succumbed to multiorgan failure. CONCLUSIONS: After a systematic review of the literature, we found that this disease predominantly affects females, with pediatric cases exceedingly rare. Fulminant myocarditis (FM) progresses rapidly, poses significant treatment challenges sporadic, and carries a poor prognosis. Interestingly, literature reports suggest that anti-thymocyte globulin therapy may have a positive impact in treating FM, potentially offering new insights into its pathogenesis and clinical management.
Sujet(s)
Virus influenza B , Grippe humaine , Myocardite , Enfant , Humains , Mâle , Oxygénation extracorporelle sur oxygénateur à membrane , Issue fatale , Grippe humaine/complications , Grippe humaine/virologie , Myocardite/virologie , Myocardite/étiologieRÉSUMÉ
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2-14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13-5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use. Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382.
Sujet(s)
Antiviraux , Dibenzothiépines , Virus influenza B , Grippe humaine , Morpholines , Oséltamivir , Patients en consultation externe , Pyridones , Triazines , Humains , Grippe humaine/traitement médicamenteux , Dibenzothiépines/usage thérapeutique , Oséltamivir/usage thérapeutique , Antiviraux/usage thérapeutique , Mâle , Études rétrospectives , Femelle , Adulte d'âge moyen , Adulte , Pyridones/usage thérapeutique , Morpholines/usage thérapeutique , Triazines/usage thérapeutique , Sujet âgé , Virus influenza B/effets des médicaments et des substances chimiques , Jeune adulte , Adolescent , Hospitalisation/statistiques et données numériques , Enfant , Pyridines/usage thérapeutique , Japon/épidémiologie , Enfant d'âge préscolaire , Résultat thérapeutique , Nourrisson , Sujet âgé de 80 ans ou plusRÉSUMÉ
Since 2019, COVID-19 has been raging around the world. Respiratory viral infectious diseases such as influenza and respiratory syncytial virus (RSV) infection are also prevalent, with influenza having the ability to cause seasonal pandemics. While vaccines and antiviral drugs are available to prevent and treat disease, herbal extracts would be another option. This study investigated the inhibitory effects of extracts of Echinacea purpurea (EP) and Ganoderma lucidum (G. lucidum) and the advanced G. lucidum drink (AG) on influenza A/B viruses. To determine whether EP and G. lucidum extracts enhance cell immunity and thus prevent virus infection or act to directly suppress viruses, cell survival and hemagglutination (HA) assays were used in this study. Cells were treated with samples at different concentrations (each sample concentration was tested from the highest non-cytotoxic concentration) and incubated with influenza A/B for 24 h, with the results showing that both G. lucidum and EP extracts and mixtures exhibited the ability to enhance cell survival against viruses. In the HA assay, AG and EP extract showed good inhibitory effect on influenza A/B viruses. All of the samples demonstrated an improvement of the mitochondrial membrane potential and improved resistance to influenza A/B virus infection. EP and G. lucidum extracts at noncytotoxic concentrations increased cell viability, but only AG and EP extract directly decreased influenza virus titers. In conclusion, results indicate the ability of EP and G. lucidum extract to prevent viruses from entering cells by improving cell viability and mitochondrial dysfunction and EP extract showed direct inhibition on viruses and prevented viral infection at post-infection strategy.
Sujet(s)
Antiviraux , Survie cellulaire , Echinacea , Virus de la grippe A , Virus influenza B , Grippe humaine , Extraits de plantes , Reishi , Reishi/composition chimique , Virus influenza B/effets des médicaments et des substances chimiques , Antiviraux/pharmacologie , Antiviraux/composition chimique , Echinacea/composition chimique , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Humains , Survie cellulaire/effets des médicaments et des substances chimiques , Grippe humaine/traitement médicamenteux , Grippe humaine/virologie , Virus de la grippe A/effets des médicaments et des substances chimiques , Animaux , Cellules rénales canines Madin-Darby , ChiensRÉSUMÉ
Introduction. After two seasons of absence and low circulation, influenza activity increased significantly in the winter of 2022-2023. This study aims to characterize virological and epidemiological aspects of influenza infection in Bulgaria during the 2022-2023 season and perform a phylogenetic/molecular analysis of the hemagglutinin (HA) and neuraminidase (NA) sequences of representative influenza strains.Hypothesis/Gap Statement. Influenza A and B viruses generate new genetic groups/clades each season, replacing previously circulating variants. This results in increased antigenic distances from current vaccine strains. Strengthening existing influenza surveillance is essential to meet the challenges posed by the co-circulation of influenza and SARS-CoV-2.Methodology. We tested 2713 clinical samples from patients with acute respiratory illnesses using a multiplex real-time RT-PCR kit (FluSC2) to detect influenza A/B and Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2) simultaneously. Representative Bulgarian influenza strains were sequenced at the WHO Collaborating Centres in London, UK, and Atlanta, USA.Results. Influenza virus was detected in 694 (25.6â%) patients. Of these, 364 (52.4â%), 213 (30.7â%) and 117 (16.9â%) were positive for influenza A(H1N1)pdm09, A(H3N2) and B/Victoria lineage virus, respectively. HA genes of the 47 influenza A(H1N1)pdm09 viruses fell into clades 5a.2. and 5a.2a.1 within the 6B.5A.1A.5a.2 group. Twenty-seven A(H3N2) viruses belonging to subclades 2b, 2a.1, 2a.1b and 2a.3a.1 within the 3C.2a1b.2a.2 group were analysed. All 23 sequenced B/Victoria lineage viruses were classified into the V1A.3a.2 group. We identified amino acid substitutions in HA and NA compared with the vaccine strains, including several substitutions in the HA antigenic sites.Conclusion. The study's findings showed genetic diversity among the influenza A viruses and, to a lesser extent, among B viruses, circulating in the first season after the lifting of anti-COVID-19 measures.
Sujet(s)
Variation génétique , Virus influenza B , Grippe humaine , Sialidase , Phylogenèse , SARS-CoV-2 , Humains , Grippe humaine/virologie , Grippe humaine/épidémiologie , Virus influenza B/génétique , Virus influenza B/classification , Virus influenza B/isolement et purification , SARS-CoV-2/génétique , SARS-CoV-2/classification , Sialidase/génétique , Adulte , Mâle , Adulte d'âge moyen , Femelle , Bulgarie/épidémiologie , Jeune adulte , Sujet âgé , Glycoprotéine hémagglutinine du virus influenza/génétique , Enfant d'âge préscolaire , Enfant , Adolescent , COVID-19/épidémiologie , COVID-19/virologie , Nourrisson , Saisons , Virus de la grippe A/génétique , Virus de la grippe A/classification , Virus de la grippe A/isolement et purification , Sous-type H1N1 du virus de la grippe A/génétique , Sous-type H1N1 du virus de la grippe A/classification , Sous-type H1N1 du virus de la grippe A/isolement et purification , Sous-type H3N2 du virus de la grippe A/génétique , Sous-type H3N2 du virus de la grippe A/classification , Sous-type H3N2 du virus de la grippe A/isolement et purificationRÉSUMÉ
Seasonal increase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus A/B (Flu A/B), and respiratory syncytial virus (RSV) require rapid diagnostic test methods for the management of respiratory tract infections. In this study, we compared the diagnostic accuracy of Savanna RVP4 (RVP4, QuidelOrtho) with Xpert Xpress Plus SARS-CoV-2/Flu/RSV (Xpert, Cepheid). Nasopharyngeal swabs from patients treated at a tertiary care hospital (Germany) were tested for SARS-CoV-2, Flu A/B, and RSV by RVP4 to assess diagnostic accuracy (reference standard: Xpert). The intra and inter assay precision of Ct-values was assessed by repeated test in triplicates (on day 1) and duplicates (days 2-3). All patients with a physician's order for a multiplex test for SARS-CoV-2, Flu, and RSV test were included. Duplicate swabs from the same patient, samples with a total volume ≤1 mL, or inappropriate shipment/storage were excluded. In total, 229 swabs were included between September 2023 and February 2024. The concordance between both tests was 96.5% (SARS-CoV-2), 98.7% (Flu A), and 99.6% (RSV). Flu B was not detected by both tests. The RVP4 test had a sensitivity of 85%-95% and a specificity of 100% for the detection of SARS-CoV-2, Flu A, and RSV. The intra and inter assay precision of Ct-values from RVP4 was 3% and 2% (SARS-CoV-2), 5% and 4% (Flu A), and 0% and 3% (RSV), respectively. The Savanna RVP4 has a favorable diagnostic accuracy for the detection of SARS-CoV-2, Flu A, and RSV. IMPORTANCE: We assessed the diagnostic accuracy of a new point-of-care test for the rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus A/B (Flu A/B), and respiratory syncytial virus (RSV). The new test has a concordance with the reference standard of 96.5% (SARS-CoV-2), 98.7% (Flu A), and 99.1% (RSV). The sensitivity of 85%-95% and specificity of 100% for the detection of SARS-CoV-2, Flu A, and RSV is comparable with similar nucleic acid amplification-based point of care tests but at lower costs.
Sujet(s)
COVID-19 , Virus de la grippe A , Grippe humaine , Infections à virus respiratoire syncytial , SARS-CoV-2 , Sensibilité et spécificité , Humains , COVID-19/diagnostic , SARS-CoV-2/isolement et purification , SARS-CoV-2/génétique , Virus de la grippe A/isolement et purification , Grippe humaine/diagnostic , Grippe humaine/virologie , Infections à virus respiratoire syncytial/diagnostic , Infections à virus respiratoire syncytial/virologie , Virus influenza B/isolement et purification , Partie nasale du pharynx/virologie , Femelle , Virus respiratoire syncytial humain/isolement et purification , Virus respiratoire syncytial humain/génétique , Adulte d'âge moyen , Mâle , Adulte , Sujet âgé , Infections de l'appareil respiratoire/diagnostic , Infections de l'appareil respiratoire/virologie , Allemagne , Virus respiratoires syncytiaux/isolement et purificationRÉSUMÉ
The aim of this study was to determine the level of anti-hemagglutinin antibodies in blood sera collected from patients during the 2022/2023 epidemic season in Poland. A total of 700 sera samples from patients across the country were tested. The samples were divided into seven groups according to the age of the patients, with 100 samples from each age group. The hemagglutination inhibition test (OZHA) was used to determine the level of anti-hemagglutinin antibodies. The test results have confirmed the presence of anti-hemagglutinin antibodies for antigens A/Victoria/2570/2019 (H1N1)pdm09, A/Darwin/9/2021 (H3N2), B/Austria/1359417/2021 (B/Yamagata lineage) and B/ Phuket/3073/2013 (B/Victoria lineage) present in the influenza vaccine recommended by the World Health Organization (WHO) for the 2022/2023 epidemic season. The highest geometric mean antibody titres (GMT) and protection rate values (%) were recorded for hemagglutinin A/H3N2. In Poland, in the 2022/2023 epidemic season, the percentage of the population vaccinated against influenza was 5.7%. Therefore, the test results can be interpreted as the response of the immune system in patients who have been previously infected with an influenza virus.
Sujet(s)
Anticorps antiviraux , Tests d'inhibition de l'hémagglutination , Glycoprotéine hémagglutinine du virus influenza , Sous-type H3N2 du virus de la grippe A , Grippe humaine , Humains , Pologne/épidémiologie , Grippe humaine/immunologie , Grippe humaine/épidémiologie , Grippe humaine/virologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Adulte , Adulte d'âge moyen , Glycoprotéine hémagglutinine du virus influenza/immunologie , Adolescent , Jeune adulte , Mâle , Sous-type H3N2 du virus de la grippe A/immunologie , Femelle , Enfant , Enfant d'âge préscolaire , Vaccins antigrippaux/immunologie , Sous-type H1N1 du virus de la grippe A/immunologie , Sujet âgé , Épidémies , Saisons , Nourrisson , Virus influenza B/immunologieRÉSUMÉ
BACKGROUND: Antigenic similarity between vaccine viruses and circulating viruses is crucial for achieving high vaccine effectiveness against seasonal influenza. New non-egg-based vaccine production technologies could revise current vaccine formulation schedules. We aim to assess the potential benefit of delaying seasonal influenza vaccine virus selection decisions. METHODS: We identified seasons where season-dominant viruses presented increasing prevalence after vaccine formulation had been decided in February for the Northern Hemisphere, contributing to their antigenic discrepancy with vaccine viruses. Using a SEIR (susceptible-exposed-infectious-recovered) model of seasonal influenza in the United States, we evaluated the impact of updating vaccine decisions with more antigenically similar vaccine viruses on the influenza burden in the United States. RESULTS: In 2014-2015 and 2019-2020, the season-dominant A(H3N2) subclade and B/Victoria clade, respectively, presented increasing prevalence after vaccine decisions were already made for the Northern Hemisphere. Our model showed that the updated A(H3N2) vaccine could have averted 5000-65 000 influenza hospitalizations in the United States in 2014-2015, whereas updating the B/Victoria vaccine component did not substantially change influenza burden in the 2019-2020 season. CONCLUSIONS: With rapid vaccine production, revising current timelines for vaccine selection could result in substantial epidemiological benefits, particularly when additional data could help improve the antigenic match between vaccine and circulating viruses.
Sujet(s)
Sous-type H3N2 du virus de la grippe A , Vaccins antigrippaux , Grippe humaine , Saisons , Humains , Vaccins antigrippaux/immunologie , Vaccins antigrippaux/administration et posologie , États-Unis/épidémiologie , Grippe humaine/prévention et contrôle , Grippe humaine/épidémiologie , Grippe humaine/virologie , Sous-type H3N2 du virus de la grippe A/immunologie , Études rétrospectives , Enfant , Enfant d'âge préscolaire , Virus influenza B/immunologie , Adulte , Adulte d'âge moyen , Hospitalisation/statistiques et données numériques , Adolescent , Jeune adulte , Sujet âgé , , Nourrisson , Vaccination/statistiques et données numériquesRÉSUMÉ
BACKGROUND: The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers. METHODS: We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers. RESULTS: The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria. CONCLUSIONS: HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons.
Sujet(s)
Anticorps antiviraux , Tests d'inhibition de l'hémagglutination , Sous-type H1N1 du virus de la grippe A , Sous-type H3N2 du virus de la grippe A , Virus influenza B , Vaccins antigrippaux , Grippe humaine , , Humains , Vaccins antigrippaux/immunologie , Vaccins antigrippaux/administration et posologie , Grippe humaine/prévention et contrôle , Grippe humaine/immunologie , Sous-type H1N1 du virus de la grippe A/immunologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Sous-type H3N2 du virus de la grippe A/immunologie , Femelle , Virus influenza B/immunologie , Mâle , Enfant d'âge préscolaire , Enfant , Nourrisson , Vaccins inactivés/immunologie , Vaccins inactivés/administration et posologieRÉSUMÉ
The development of effective methods for the surveillance of seasonal respiratory viruses is required for the timely management of outbreaks. We aimed to survey Influenza-A, Influenza-B, RSV-A, Rhinovirus and SARS-CoV-2 surveillance in a tertiary hospital and a campus over 5 months. The effectiveness of air screening as an early warning system for respiratory viruses was evaluated in correlation with respiratory tract panel test results. The overall viral positivity was higher on the campus than in the hospital (55.0% vs. 38.0%). Influenza A was the most prevalent pathogen in both locations. There were two influenza peaks (42nd and 49th weeks) in the hospital air, and a delayed peak was detected on campus in the 1st-week of January. Panel tests indicated a high rate of Influenza A in late December. RSV-A-positivity was higher on the campus than the hospital (21.6% vs. 7.4%). Moreover, we detected two RSV-A peaks in the campus air (48th and 51st weeks) but only one peak in the hospital and panel tests (week 49). Although rhinovirus was the most common pathogen in panel tests, rhinovirus positivity was low in air samples. The air screening for Influenza-B and SARS-Cov-2 revealed comparable positivity rates with panel tests. Air screening can be integrated into surveillance programs to support infection control programs for potential epidemics of respiratory virus infections except for rhinoviruses.
Sujet(s)
COVID-19 , Rhinovirus , SARS-CoV-2 , Humains , Rhinovirus/isolement et purification , SARS-CoV-2/isolement et purification , SARS-CoV-2/génétique , COVID-19/épidémiologie , COVID-19/diagnostic , COVID-19/virologie , Aérosols/analyse , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/épidémiologie , Infections de l'appareil respiratoire/diagnostic , Microbiologie de l'air , Grippe humaine/épidémiologie , Grippe humaine/virologie , Pollution de l'air intérieur/analyse , Virus de la grippe A/isolement et purification , Saisons , Épidémies , Surveillance de l'environnement/méthodes , Virus influenza B/isolement et purification , Virus/isolement et purification , Virus/classification , Virus/génétiqueRÉSUMÉ
The immune response to inactivated influenza vaccines (IIV) is influenced by multiple factors, including hemagglutinin content and egg-based manufacturing. Only two US-licensed vaccines are manufactured without egg passage: cell culture-based inactivated vaccine (ccIIV) and recombinant vaccine (RIV). We conducted a randomized open-label trial in central Wisconsin during the 2018-19 and 2019-20 seasons to compare immunogenicity of sequential vaccination. Participants 18-64 years old were randomized 1:1:1 to receive RIV, ccIIV or IIV in strata defined by number of influenza vaccine doses in the prior 3 years. They were revaccinated with the same product in year two. Paired serum samples were tested by hemagglutination inhibition against egg-adapted and cell-grown vaccine viruses. Serologic endpoints included geometric mean titer (GMT), mean fold rise, and percent seroconversion. There were 373 participants randomized and vaccinated in 2018-19; 332 were revaccinated in 2019-20. In 2018-19, RIV and ccIIV were not more immunogenic than IIV against A/H1N1. The post-vaccination GMT against the cell-grown 3C.2a A/H3N2 vaccine virus was higher for RIV vs IIV (p = .001) and RIV vs ccIIV (p = .001). The antibody response to influenza B viruses was similar across study arms. In 2019-20, GMT against the cell-grown 3C.3a A/H3N2 vaccine virus was higher for RIV vs IIV (p = .03) and for RIV vs ccIIV (p = .001). RIV revaccination generated significantly greater backboosting to the antigenically distinct 3C.2a A/H3N2 virus (2018-19 vaccine strain) compared to ccIIV or IIV. This study adds to the evidence that RIV elicits a superior immunologic response against A/H3N2 viruses compared to other licensed influenza vaccine products.